Inherited Thrombocytopenias

Platelets

Volumn , Issue , 2013, Pages 971-987

  Lambert, Michelle P ^a   Poncz, Mortimer ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84882572753     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B978-0-12-387837-3.00047-X     Document Type: Chapter

References (188)

1. Zeller B., Rajantie J., Hedlund-Treutiger I., et al. NOPHO ITP. Childhood idiopathic thrombocytopenic purpura in the Nordic countries: epidemiology and predictors of chronic disease. Acta Paediatr 2005, 94:178-184.
2. Sutor A., Harms A., Kaufmehl K. Acute immune thrombocytopenia (ITP) in childhood: retrospective and prospective survey in Germany. Semin Thromb Hemost 2001, 27:253-267.
3. Drachman J. Inherited thrombocytopenia: when a low platelet count does not mean ITP. Blood 2004, 103:390-398.
4. Lambert M. What to do when you suspect an inherited platelet disorder. Hematology Am Soc Hematol Educ Program 2011, 2011:377-383.
5. Corash L., Shafer B., Blaese R. Platelet-associated immunoglobulin, platelet size, and the effect of splenectomy in the Wiskott-Aldrich syndrome. Blood 1985, 65:1439-1443.
6. Imai K., Morio T., Zhu Y., et al. Clinical course of patients with WASP gene mutations. Blood 2004, 103:456-464.
7. Thrasher A.J. New insights into the biology of Wiskott-Aldrich syndrome (WAS). Hematology Am Soc Hematol Educ Program 2009, 132-138.
8. Orange J., Stone K., Turvey S., Krzewski K. The Wiskott-Aldrich syndrome. Cell Mol Life Sci 2004, 61:2361-2385.
9. Ochs H. The Wiskott-Aldrich syndrome. Clin Rev Allergy Immunol 2001, 20:61-86.
10. Derry J., Kerns J., Weinberg K., et al. WASP gene mutations in Wiskott-Aldrich syndrome and X-linked thrombocytopenia. Hum Mol Genet 1995, 4:1127-1135.
11. Snapper S., Rosen F. A family of WASPs. N Engl J Med 2003, 348:350-351.
12. Snapper S., Rosen F. The Wiskott-Aldrich syndrome protein (WASP): roles in signaling and cytoskeletal organization. Annu Rev Immunol 1999, 17:905-929.
13. Notarangelo L.D., Mazza C., Giliani S., et al. Missense mutations of the WASP gene cause intermittent X-linked thrombocytopenia. Blood 2002, 99:2268-2269.
14. Blundell M.P., Worth A., Bouma G., Thrasher A.J. The Wiskott-Aldrich syndrome: the actin cytoskeleton and immune cell function. Dis Markers 2010, 29:157-175.
15. Haddad E., Cramer E., Riviere C., et al. The thrombocytopenia of Wiskott Aldrich syndrome is not related to a defect in proplatelet formation. Blood 1999, 94:509-518.
16. Litzman J., Jones A., Hann I., Chapel H., Strobel S., Morgan G. Intravenous immunoglobulin, splenectomy, and antibiotic prophylaxis in Wiskott-Aldrich syndrome. Arch Dis Child 1996, 75:436-439.
17. Sullivan K. Recent advances in our understanding of Wiskott-Aldrich syndrome. Curr Opin Hematol 1999, 6:8-14.
18. Ariga T., Nakajima M., Yoshida J., et al. Confirming or excluding the diagnosis of Wiskott-Aldrich syndrome in children with thrombocytopenia of an unknown etiology. J Pediatr Hematol Oncol 2004, 26:435-440.
19. Lum L., Tubergen D., Corash L., Blaese R. Splenectomy in the management of the thrombocytopenia of the Wiskott-Aldrich syndrome. N Engl J Med 1980, 302:892-896.
20. Filipovich A.H., Stone J.V., Tomany S.C., et al. Impact of donor type on outcome of bone marrow transplantation for Wiskott-Aldrich syndrome: collaborative study of the International Bone Marrow Transplant Registry and the National Marrow Donor Program. Blood 2001, 97:1598-1603.
21. Azuma H., Sakata H., Saijyou M., Okuno A. Effect of interleukin 2 on intractable herpes virus infection and chronic eczematoid dermatitis in a patient with Wiskott-Aldrich syndrome. Eur J Pediatr 1993, 152:998-1000.
22. Azuma H., Oshima M., Ito K., et al. Impaired interleukin-2 production in T-cells from a patient with Wiskott-Aldrich syndrome: basis of clinical effect of interleukin-2 replacement therapy. Eur J Pediatr 2000, 159:633-634.
23. Ozsahin H., Cavazzana-Calvo M., Notarangelo L.D., et al. Long-term outcome following hematopoietic stem-cell transplantation in Wiskott-Aldrich syndrome: collaborative study of the European Society for Immunodeficiencies and European Group for Blood and Marrow Transplantation. Blood 2008, 111:439-445.
24. Galy A., Roncarolo M.G., Thrasher A.J. Development of lentiviral gene therapy for Wiskott-Aldrich syndrome. Expert Opin Biol Ther 2008, 8:181-190.
25. Perry Gr Spector B, Schuman L., et al. The WiskottAldrich syndrome in the United States and Canada (1892-1979). J Pediatr 1980, 97:72-78.
26. Sullivan K., Mullen C., Blaese R., Winkelstein J. A multiinstitutional survey of the Wiskott-Aldrich syndrome. J Pediatr 1994, 125:876-885.
27. Geddis A.E., Kaushansky K. Inherited thrombocytopenias: toward a molecular understanding of disorders of platelet production. Curr Opin Pediatr 2004, 16:15-22.
28. Geddis A.E. Congenital amegakaryocytic thrombocytopenia. Pediatr Blood Cancer 2011, 57:199-203.
29. Ballmaier M., Germeshausen M., Krukemeier S., Welte K. Thrombopoietin is essential for the maintenance of normal hematopoiesis in humans: development of aplastic anemia in patients with congenital amegakaryocytic thrombocytopenia. Ann N Y Acad Sci 2003, 996:17-25.
30. Muraoka K., Ishii E., Tsuji K., et al. Defective response to thrombopoietin and impaired expression of c-mpl mRNA of bone marrow cells in congenital amegakaryocytic thrombocytopenia. Br J Haematol 1997, 96:287-292.
31. Ballmaier M., Germeshausen M., Schulze H., et al. c-mpl mutations are the cause of congenital amegakaryocytic thrombocytopenia. Blood 2001, 97:139-146.
32. Yesilipek, Hazar V., Kupesiz A., Yegin O. Peripheral stem cell transplantation in a child with amegakaryocytic thrombocytopenia. Bone Marrow Transplant 2000, 26:571-572.
33. Muraoka K., Ishii E., Ihara K., et al. Successful bone marrow transplantation in a patient with c-mpl-mutated congenital amegakaryocytic thrombocytopenia from a carrier donor. Pediatr Transplant 2005, 9:101-103.
34. Gounder D.S., Pullon H.W., Ockelford P.A., Nicol R.O. Clinical manifestations of the thrombocytopenia and absent radii (TAR) syndrome. Aust N Z J Med 1989, 19:479-482.
35. Martinez-Frias M.L., Bermejo Sanchez E., Garcia Garcia A., et al. [An epidemiological study of the thrombocytopenia with radial aplasia syndrome (TAR) in Spain]. An Esp Pediatr 1998, 49:619-623.
36. Hedberg V.A., Lipton J.M. Thrombocytopenia with absent radii. A review of 100 cases. Am J Pediatr Hematol Oncol 1988, 10:51-64.
37. Greenhalgh K.L., Howell R.T., Bottani A., et al. Thrombocytopenia-absent radius syndrome: a clinical genetic study. J Med Genet 2002, 39:876-881.
38. Whitfield M.F., Barr D.G. Cows' milk allergy in the syndrome of thrombocytopenia with absent radius. Arch Dis Child 1976, 51:337-343.
39. Bradshaw A., Donnelly L.F., Foreman J.W. Thrombocytopenia and absent radii (TAR) syndrome associated with horseshoe kidney. Pediatr Nephrol 2000, 14:29-31.
40. van Haeringen A., Veenstra F., Maaswinkel-Mooij P.D., van de Kamp J.J. Intermittent thrombocytopenia and absent radii: report of a patient with additional unusual manifestations. Am J Med Genet 1989, 34:202-206.
41. Anyane-Yeboa K., Jaramillo S., Nagel C., Grebin B. Tetraphocomelia in the syndrome of thrombocytopenia with absent radii (TAR syndrome). Am J Med Genet 1985, 20:571-576.
42. Skorka A., Bielicka-Cymermann J., Gieruszczak-Bialek D., Korniszewski L. Thrombocytopenia-absent radius (TAR) syndrome: a case with agenesis of corpus callosum, hypoplasia of cerebellar vermis and horseshoe kidney. Genet Couns 2005, 16:377-382.
43. Albers CA., Paul DS., Schulze H., et al. Compound inheritance of a low-frequency regulatory SNP and a rare null mutation in exon-junction complex subunit RBM8A causes TAR syndrome. Nat Genet 2012, 44:435-439.
44. Sekine I., Hagiwara T., Miyazaki H., et al. Thrombocytopenia with absent radii syndrome: studies on serum thrombopoietin levels and megakaryopoiesis in vitro. J Pediatr Hematol Oncol 1998, 20:74-78.
45. Ballmaier M., Schulze H., Strauss G., et al. Thrombopoietin in patients with congenital thrombocytopenia and absent radii: elevated serum levels, normal receptor expression, but defective reactivity to thrombopoietin. Blood 1997, 90:612-619.
46. Linch D.C., Stewart J.W., West C. Blood and bone marrow cultures in a case of thrombocytopenia with absent radii. Clin Lab Haematol 1982, 4:313-317.
47. al-Jefri A.H., Dror Y., Bussel J.B., Freedman M.H. Thrombocytopenia with absent radii: frequency of marrow megakaryocyte progenitors, proliferative characteristics, and megakaryocyte growth and development factor responsiveness. Pediatr Hematol Oncol 2000, 17:299-306.
48. Letestu R., Vitrat N., Masse A., et al. Existence of a differentiation blockage at the stage of a megakaryocyte precursor in the thrombocytopenia and absent radii (TAR) syndrome. Blood 2000, 95:1633-1641.
49. Zahavi J., Gale R., Kakkar V.V. Storage pool disease of platelets in an infant with thrombocytopenic absent radii (TAR) syndrome simulating Fanconi's anaemia. Haemost 1981, 10:121-133.
50. Bonsi L., Marchionni C., Alviano F., et al. Thrombocytopenia with absent radii (TAR) syndrome: From hemopoietic progenitor to mesenchymal stromal cell disease?. Exp Hematol 2009, 37:1-7.
51. Thompson A.A., Woodruff K., Feig S.A., Nguyen L.T., Schanen N.C. Congenital thrombocytopenia and radio-ulnar synostosis: a new familial syndrome. Br J Haematol 2001, 113:866-870.
52. Thompson A.A., Nguyen L.T. Amegakaryocytic thrombocytopenia and radio-ulnar synostosis are associated with HOXA11 mutation. Nat Genet 2000, 26:397-398.
53. Thorsteinsdottir U., Sauvageau G., Hough M.R., et al. Overexpression of HOXA10 in murine hematopoietic cells perturbs both myeloid and lymphoid differentiation and leads to acute myeloid leukemia. Mol Cell Biol 1997, 17:495-505.
54. Horvat-Switzer R.D., Thompson A.A. HOXA11 mutation in amegakaryocytic thrombocytopenia with radio-ulnar synostosis syndrome inhibits megakaryocytic differentiation in vitro. Blood Cells Mol Dis 2006, 37:55-63.
55. Sola M.C., Slayton W.B., Rimsza L.M., et al. A neonate with severe thrombocytopenia and radio-ulnar synostosis. J Perinatol 2004, 24:528-530.
56. Dowton S., Beardsley D., Jamison D., Blattner S., Li F. Studies of a familial platelet disorder. Blood 1985, 65:557.
57. Owen C. Insights into familial platelet disorder with propensity to myeloid malignancy (FPD/AML). Leuk Res 2010, 34:141-142.
58. Owen C.J., Toze C.L., Koochin A., et al. Five new pedigrees with inherited RUNX1 mutations causing familial platelet disorder with propensity to myeloid malignancy. Blood 2008, 112:4639-4645.
59. Michaud J., Wu F., Osato M., et al. In vitro analyses of known and novel RUNX1/AML1 mutations in dominant familial platelet disorder with predisposition to acute myelogenous leukemia: implications for mechanisms of pathogenesis. Blood 2002, 99:1364-1372.
60. Minelli A., Maserati E., Rossi G., et al. Familial platelet disorder with propensity to acute myelogenous leukemia: genetic heterogeneity and progression to leukemia via acquisition of clonal chromosome anomalies. Genes Chromosomes Cancer 2004, 40:165-171.
61. Simeone A., Daga A., Calabi F. Expression of runt in the mouse embryo. Dev Dyn 1995, 203:61-70.
62. Song W., Sullivan M., Legare R., et al. Haploinsufficiency of CBFA2 causes familial thrombocytopenia with propensity to develop acute myelogenous leukaemia. Nat Genet 1999, 23:166-175.
63. Basecke J., Feuring-Buske M., Brittinger G., Schaefer U., Hiddemann W., Griesinger F. Transcription of AML1 in hematopoietic subfractions of normal adults. Ann Hematol 2002, 81:254-257.
64. Beri-Dexheimer M., Latger-Cannard V., Philippe C., et al. Clinical phenotype of germline RUNX1 haploinsufficiency: from point mutations to large genomic deletions. Eur J Hum Genet 2008, 16:1014-1018.
65. Vradii D., Zaidi S.K., Lian J.B., van Wijnen A.J., Stein J.L., Stein G.S. Point mutation in AML1 disrupts subnuclear targeting, prevents myeloid differentiation, and effects a transformation-like phenotype. Proc Natl Acad Sci U S A 2005, 102:7174-7179.
66. Aneja K., Jalagadugula G., Mao G., Singh A., Rao A.K. Mechanism of platelet factor 4 (PF4) deficiency with RUNX1 haplodeficiency: RUNX1 is a transcriptional regulator of PF4. J Thromb Haemost 2010, 9:383-391.
67. Heller P.G., Glembotsky A.C., Gandhi M.J., et al. Low Mpl receptor expression in a pedigree with familial platelet disorder with predisposition to acute myelogenous leukemia and a novel AML1 mutation. Blood 2005, 105:4664-4670.
68. Miyoshi H., Shimizu K., Kozu T., Maseki N., Kaneko Y., Ohki M. t(8; 21) breakpoints on chromosome 21 in acute myeloid leukemia are clustered within a limited region of a single gene, AML1. Proc Natl Acad Sci U S A 1991, 88:10431-10434.
69. Cleary M.L. A new angle on a pervasive oncogene. Nat Genet 1999, 23:134-135.
70. Asou N. The role of a Runt domain transcription factor AML1/RUNX1 in leukemogenesis and its clinical implications. Crit Rev Oncol Hematol 2003, 45:129-150.
71. van der Crabben S., van Binsbergen E., Ausems M., Poot M., Bierings M., Buijs A. Constitutional RUNX1 deletion presenting as non-syndromic thrombocytopenia with myelodysplasia: 21q22 ITSN1 as a candidate gene in mental retardation. Leuk Res 2011, 34:e8-e12.
72. Shinawi M., Erez A., Shardy D.L., et al. Syndromic thrombocytopenia and predisposition to acute myelogenous leukemia caused by constitutional microdeletions on chromosome 21q. Blood 2008, 112:1042-1047.
73. Favier R., Douay L., Esteva B., et al. A novel genetic thrombocytopenia (Paris-Trousseau) associated with platelet inclusions, dysmegakaryopoiesis and chromosome deletion AT 11q23. C R Acad Sci III 1993, 316:698-701.
74. Breton-Gorius J., Favier R., Guichard J., et al. A new congenital dysmegakaryopoietic thrombocytopenia (Paris-Trousseau) associated with giant platelet alpha-granules and chromosome 11 deletion at 11q23. Blood 1995, 85:1805-1814.
75. Mattina T., Perrotta C.S., Grossfeld P. Jacobsen syndrome. Orphanet J Rare Dis 2009, 4:9.
76. Truong A.H., Ben-David Y. The role of Fli-1 in normal cell function and malignant transformation. Oncogene 2000, 19:6482-6489.
77. Masuya M., Moussa O., Abe T., et al. Dysregulation of granulocyte, erythrocyte, and NK cell lineages in Fli-1 gene-targeted mice. Blood 2005, 105:95-102.
78. Anderson M.K., Hernandez-Hoyos G., Diamond R.A., Rothenberg E.V. Precise developmental regulation of Ets family transcription factors during specification and commitment to the T cell lineage. Development 1999, 126:3131-3148.
79. Jackers P., Szalai G., Moussa O., Watson D.K. Ets-dependent regulation of target gene expression during megakaryopoiesis. J Biol Chem 2004, 279:52183-52190.
80. Hu W., Philips A.S., Kwok J.C., Eisbacher M., Chong B.H. Identification of nuclear import and export signals within Fli-1: roles of the nuclear import signals in Fli-1-dependent activation of megakaryocyte-specific promoters. Mol Cell Biol 2005, 25:3087-3108.
81. Wang X., Crispino J.D., Letting D.L., Nakazawa M., Poncz M., Blobel G.A. Control of megakaryocyte-specific gene expression by GATA-1 and FOG-1: role of Ets transcription factors. Embo J 2002, 21:5225-5234.
82. Kawada H., Ito T., Pharr P.N., Spyropoulos D.D., Watson D.K., Ogawa M. Defective megakaryopoiesis and abnormal erythroid development in Fli-1 gene-targeted mice. Int J Hematol 2001, 73:463-468.
83. Hart A., Melet F., Grossfeld P., et al. Fli-1 is required for murine vascular and megakaryocytic development and is hemizygously deleted in patients with thrombocytopenia. Immunity 2000, 13:167-177.
84. Raslova H., Komura E., Le Couedic J.P., et al. FLI1 monoallelic expression combined with its hemizygous loss underlies Paris-Trousseau/Jacobsen thrombopenia. J Clin Invest 2004, 114:77-84.
85. Savoia A., Del Vecchio M., Totaro A., et al. An autosomal dominant thrombocytopenia gene maps to chromosomal region 10p. Am J Hum Genet 1999, 65:1401-1405.
86. Drachman J.G., Jarvik G.P., Mehaffey M.G. Autosomal dominant thrombocytopenia: incomplete megakaryocyte differentiation and linkage to human chromosome 10. Blood 2000, 96:118-125.
87. Gandhi M.J., Cummings C.L., Drachman J.G. FLJ14813 missense mutation: a candidate for autosomal dominant thrombocytopenia on human chromosome 10. Hum Hered 2003, 55:66-70.
88. Punzo F., Mientjes E.J., Rohe C.F., et al. A mutation in the acyl-coenzyme A binding domain-containing protein 5 gene (ACBD5) identified in autosomal dominant thrombocytopenia. J Thromb Haemost 2010, 8:2085-2087.
89. Pippucci T., Savoia A., Perrotta S., et al. Mutations in the 5' UTR of ANKRD26, the ankirin repeat domain 26 gene, cause an autosomal-dominant form of inherited thrombocytopenia, THC2. Am J Hum Genet 2011, 88:115-120.
90. Noris P., Perrotta S., Seri M., et al. Mutations in ANKRD26 are responsible for a frequent form of inherited thrombocytopenia: analysis of 78 patients from 21 families. Blood 2011, 117:6673-6680.
91. Sabri S., Jandrot-Perrus M., Bertoglio J., et al. Differential regulation of actin stress fiber assembly and proplatelet formation by alpha2beta1 integrin and GPVI in human megakaryocytes. Blood 2004, 104:3117-3125.
92. Oliveira R.A., Takadachi M.M., Nonoyama K., Barretto O.C. Is automated platelet counting still a problem in thrombocytopenic blood?. Sao Paulo Med J 2003, 121:19-23.
93. Bernard J., Soulier J.-P. Sur une nouvelle variete de dystrophie thrombocytaire-hemoragipare congenitale. Sem Hop Paris 1948, 24:3217-3223.
94. Lopez J.A., Andrews R.K., Afshar-Kharghan V., Berndt M.C. Bernard-Soulier syndrome. Blood 1998, 91:4397-4418.
95. Kunishima S., Kamiya T., Saito H. Genetic abnormalities of Bernard-Soulier syndrome. Int J Hematol 2002, 76:319-327.
96. Hillmann A., Nurden A., Nurden P., et al. A novel hemizygous Bernard-Soulier syndrome (BSS) mutation in the amino terminal domain of glycoprotein (GP)Ibbeta-platelet characterization and transfection studies. Thromb Haemost 2002, 88:1026-1032.
97. Watanabe R., Ishibashi T., Saitoh Y., et al. Bernard-Soulier syndrome with a homozygous 13 base pair deletion in the signal peptide-coding region of the platelet glycoprotein Ib(beta) gene. Blood Coagul Fibrinolysis 2003, 14:387-394.
98. Sachs U.J., Kroll H., Matzdorff A.C., Berghofer H., Lopez J.A., Santoso S. Bernard-Soulier syndrome due to the homozygous Asn-45Ser mutation in GPIX: an unexpected, frequent finding in Germany. Br J Haematol 2003, 123:127-131.
99. Lanza F., De La Salle C., Baas M.J., et al. A Leu7Pro mutation in the signal peptide of platelet glycoprotein (GP)IX in a case of Bernard-Soulier syndrome abolishes surface expression of the GPIb-V-IX complex. Br J Haematol 2002, 118:260-266.
100. Ni H., Ramakrishnan V., Ruggeri Z.M., Papalia J.M., Phillips D.R., Wagner D.D. Increased thrombogenesis and embolus formation in mice lacking glycoprotein V. Blood 2001, 98:368-373.
101. Kahn M.L., Diacovo T.G., Bainton D.F., Lanza F., Trejo J., Coughlin S.R. Glycoprotein V-deficient platelets have undiminished thrombin responsiveness and do not exhibit a Bernard-Soulier phenotype. Blood 1999, 94:4112-4121.
102. Drouin A., Favier R., Masse J.M., et al. Newly recognized cellular abnormalities in the gray platelet syndrome. Blood 2001, 98:1382-1391.
103. Gonzalez-Manchon C., Larrucea S., Pastor A.L., et al. Compound heterozygosity of the GPIbalpha gene associated with Bernard-Soulier syndrome. Thromb Haemost 2001, 86:1385-1391.
104. Bernard J. History of congenital hemorrhagic thrombocytopathic dystrophy. Blood Cells 1983, 9:179-193.
105. Canobbio I., Balduini C., Torti M. Signalling through the platelet glycoprotein Ib-V-IX complex. Cell Signal 2004, 16:1329-1344.
106. Kenny D., Morateck P.A., Gill J.C., Montgomery R.R. The critical interaction of glycoprotein (GP) IBbeta with GPIX-a genetic cause of Bernard-Soulier syndrome. Blood 1999, 93:2968-2975.
107. Plow E.F., McEver R.P., Coller B.S., Woods V.L., Marguerie G.A., Ginsberg M.H. Related binding mechanisms for fibrinogen, fibronectin, von Willebrand factor, and thrombospondin on thrombin-stimulated human platelets. Blood 1985, 66:724-727.
108. Nichols W.L., Kaese S.E., Gastineau D.A., Otteman L.A., Bowie E.J. Bernard-Soulier syndrome: whole blood diagnostic assays of platelets. Mayo Clin Proc 1989, 64:522-530.
109. Jackson S.P., Nesbitt W.S., Kulkarni S. Signaling events underlying thrombus formation. J Thromb Haemost 2003, 1:1602-1612.
110. Ware J., Russell S., Ruggeri Z.M. Generation and rescue of a murine model of platelet dysfunction: the Bernard-Soulier syndrome. Proc Natl Acad Sci U S A 2000, 97:2803-2808.
111. Hourdille P., Pico M., Jandrot-Perrus M., Lacaze D., Lozano M., Nurden A.T. Studies on the megakaryocytes of a patient with the Bernard-Soulier syndrome. Br J Haematol 1990, 76:521-530.
112. Strassel C., Eckly A., Leon C., et al. Intrinsic impaired proplatelet formation and microtubule coil assembly of megakaryocytes in a mouse model of Bernard-Soulier syndrome. Haematologica 2009, 94:800-810.
113. Eckly A., Strassel C., Freund M., et al. Abnormal megakaryocyte morphology and proplatelet formation in mice with megakaryocyte-restricted MYH9 inactivation. Blood 2009, 113:3182-3189.
114. Tomer A., Scharf R.E., McMillan R., Ruggeri Z.M., Harker L.A. Bernard-Soulier syndrome: quantitative characterization of megakaryocytes and platelets by flow cytometric and platelet kinetic measurements. Eur J Haematol 1994, 52:193-200.
115. Peitsidis P., Datta T., Pafilis I., Otomewo O., Tuddenham E.G., Kadir R.A. Bernard Soulier syndrome in pregnancy: a systematic review. Haemophilia 2010, 16:584-591.
116. Mitsui T., Yokoyama S., Yazaki N., et al. Severe bleeding tendency in a patient with Bernard-Soulier syndrome associated with a homozygous single base pair deletion in the gene coding for the human platelet glycoprotein Ibalpha. J Pediatr Hematol Oncol 1998, 20:246-251.
117. McGill M., Jamieson G.A., Drouin J., Cho M.S., Rock G.A. Morphometric analysis of platelets in Bernard-Soulier syndrome: size and configuration in patients and carriers. Thromb Haemost 1984, 52:37-41.
118. Balduini C.L., Iolascon A., Savoia A. Inherited thrombocytopenias: from genes to therapy. Haematologica 2002, 87:860-880.
119. Balduini A., Malara A., Pecci A., et al. Proplatelet formation in heterozygous Bernard-Soulier syndrome type Bolzano. J Thromb Haemost 2009, 7:478-484.
120. Savoia A., Balduini C.L., Savino M., et al. Autosomal dominant macrothrombocytopenia in Italy is most frequently a type of heterozygous Bernard-Soulier syndrome. Blood 2001, 97:1330-1335.
121. Bolton-Maggs P.H., Chalmers E.A., Collins P.W., et al. A review of inherited platelet disorders with guidelines for their management on behalf of the UKHCDO. Br J Haematol 2006, 135:603-633.
122. Kemahli S., Canatan D., Uysal Z., Akar N., Cin S., Arcasoy A. DDAVP shortens bleeding time in Bernard-Soulier syndrome. Thromb Haemost 1994, 71:675.
123. Greinacher A., Potzsch B., Kiefel V., White J.G., Muller-Berghaus G., Mueller-Eckhardt C. Evidence that DDAVP transiently improves hemostasis in Bernard-Soulier syndrome independent of von Willebrand factor. Ann Hematol 1993, 67:149-150.
124. Tonda R., Galan A.M., Pino M., Lozano M., Ordinas A., Escolar G. Hemostatic effect of activated recombinant factor VIIa in Bernard-Soulier syndrome: studies in an in vitro model. Transfusion 2004, 44:1790-1791.
125. Almeida A.M., Khair K., Hann I., Liesner R. The use of recombinant factor VIIa in children with inherited platelet function disorders. Br J Haematol 2003, 121:477-481.
126. Sharma J.B., Buckshee K, Sharma S. Puberty menorrhagia due to Bernard-Soulier syndrome and its successful treatment by 'Ovral' hormonal tablets. Aust N Z J Obstet Gynaecol 1991, 31:369-370.
127. Sullivan K.E. Chromosome 22q11.2 deletion syndrome: DiGeorge syndrome/velocardiofacial syndrome. Immunol Allergy Clin North Am 2008, 28:353-366.
128. McDonald-McGinn D.M., Sullivan K.E. Chromosome 22q11.2 deletion syndrome (DiGeorge syndrome/velocardiofacial syndrome). Medicine (Baltimore) 2011, 90:1-18.
129. Van Geet C., Devriendt K., Eyskens B., Vermylen J., Hoylaerts M.F. Velocardiofacial syndrome patients with a heterozygous chromosome 22q11 deletion have giant platelets. Pediatr Res 1998, 44:607-611.
130. Ludlow L.B., Schick B.P., Budarf M.L., et al. Identification of a mutation in a GATA binding site of the platelet glycoprotein Ibbeta promoter resulting in the Bernard-Soulier syndrome. J Biol Chem 1996, 271:22076-22080.
131. Levy A., Michel G., Lemerrer M., Philip N. Idiopathic thrombocytopenic purpura in two mothers of children with DiGeorge sequence: A new component manifestation of deletion 22q11?. Am J Med Genet 1997, 69:356-359.
132. DePiero A.D., Lourie E.M., Berman B.W., Robin N.H., Zinn A.B., Hostoffer R.W. Recurrent immune cytopenias in two patients with DiGeorge/velocardiofacial syndrome. J Pediatr 1997, 131:484-486.
133. Kratz C.P., Niehues T., Lyding S., Heusch A., Janssen G., Gobel U. Evans syndrome in a patient with chromosome 22q11.2 deletion syndrome: a case report. Pediatr Hematol Oncol 2003, 20:167-172.
134. Behrens W.E. Mediterranean macrothrombocytopenia. Blood 1975, 46:199-208.
135. Gresele P., Falcinelli E., Giannini S., et al. Dominant inheritance of a novel integrin beta3 mutation associated with a hereditary macrothrombocytopenia and platelet dysfunction in two Italian families. Haematologica 2009, 94:663-669.
136. Fabris F., Cordiano I., Salvan F., et al. Chronic isolated macrothrombocytopenia with autosomal dominant transmission: a morphological and qualitative platelet disorder. Eur J Haematol 1997, 58:40-45.
137. Fabris F., Fagioli F., Basso G., Girolami A. Autosomal dominant macrothrombocytopenia with ineffective thrombopoiesis. Haematologica 2002, 87:ELT27.
138. Weiss H.J., Meyer D., Rabinowitz R., et al. Pseudo-von Willebrand's disease. An intrinsic platelet defect with aggregation by unmodified human factor VIII/von Willebrand factor and enhanced adsorption of its high-molecular-weight multimers. N Engl J Med 1982, 306:326-333.
139. Russell S.D., Roth G.J. Pseudo-von Willebrand disease: a mutation in the platelet glycoprotein Ib alpha gene associated with a hyperactive surface receptor. Blood 1993, 81:1787-1791.
140. Holmberg L., Nilsson I.M., Borge L., Gunnarsson M., Sjorin E. Platelet aggregation induced by 1-desamino-8-D-arginine vasopressin (DDAVP) in Type IIB von Willebrand's disease. N Engl J Med 1983, 309:816-821.
141. Rodeghiero F., Castaman G. Treatment of von Willebrand disease. Semin Hematol 2005, 42:29-35.
142. Takahashi H. Replacement therapy in platelet-type von Willebrand disease. Am J Hematol 1985, 18:351-362.
143. Favaloro E.J., Lillicrap D., Lazzari M.A., et al. von Willebrand disease: laboratory aspects of diagnosis and treatment. Haemophilia 2004, 10(Suppl. 4):164-168.
144. Mathew P., Greist A., Maahs J.A., Lichtenberg E.C., Shapiro A.D. Type 2B vWD: the varied clinical manifestations in two kindreds. Haemophilia 2003, 9:137-144.
145. Keeney S., Cumming A.M. The molecular biology of von Willebrand disease. Clin Lab Haematol 2001, 23:209-230.
146. Milton J.G., Frojmovic M.M., Tang S.S., White J.G. Spontaneous platelet aggregation in a hereditary giant platelet syndrome (MPS). Am J Pathol 1984, 114:336-345.
147. Okita J.R., Frojmovic M.M., Kristopeit S., Wong T., Kunicki T.J. Montreal platelet syndrome: a defect in calcium-activated neutral proteinase (calpain). Blood 1989, 74:715-721.
148. Jackson S.C., Sinclair G.D., Cloutier S., Duan Z., Rand M.L., Poon M.C. The Montreal platelet syndrome kindred has type 2B von Willebrand disease with the VWF V1316M mutation. Blood 2009, 113:3348-3351.
149. Seri M., Pecci A., Di Bari F., et al. MYH9-related disease: May-Hegglin anomaly, Sebastian syndrome, Fechtner syndrome, and Epstein syndrome are not distinct entities but represent a variable expression of a single illness. Medicine (Baltimore) 2003, 82:203-215.
150. Seri M., Cusano R., Gangarossa S., et al. Mutations in MYH9 result in the May-Hegglin anomaly, and Fechtner and Sebastian syndromes. The May-Hegglin/Fechtner Syndrome Consortium. Nat Genet 2000, 26:103-105.
151. Heath K.E., Campos-Barros A., Toren A., et al. Nonmuscle myosin heavy chain IIA mutations define a spectrum of autosomal dominant macrothrombocytopenias: May-Hegglin anomaly and Fechtner, Sebastian, Epstein, and Alport-like syndromes. Am J Hum Genet 2001, 69:1033-1045.
152. Savoia A., De Rocco D., Panza E., et al. Heavy chain myosin 9-related disease (MYH9-RD): neutrophil inclusions of myosin-9 as a pathognomonic sign of the disorder. Thromb Haemost 2010, 103:826-832.
153. Balduini C.L., Pecci A., Savoia A. Recent advances in the understanding and management of MYH9-related inherited thrombocytopenias. Br J Haematol 2011, 154:161-174.
154. Di Pumpo M., Noris P., Pecci A., et al. Defective expression of GPIb/IX/V complex in platelets from patients with May-Hegglin anomaly and Sebastian syndrome. Haematologica 2002, 87:943-947.
155. Dong F., Li S., Pujol-Moix N., et al. Genotype-phenotype correlation in MYH9-related thrombocytopenia. Br J Haematol 2005, 130:620-627.
156. Marigo V., Nigro A., Pecci A., et al. Correlation between the clinical phenotype of MYH9-related disease and tissue distribution of class II nonmuscle myosin heavy chains. Genomics 2004, 83:1125-1133.
157. Hamilton R.W., Shaikh B.S., Ottie J.N., Storch A.E., Saleem A., White J.G. Platelet function, ultrastructure, and survival in the May-Hegglin anomaly. Am J Clin Pathol 1980, 74:663-668.
158. Wei Q., Adelstein R.S. Conditional expression of a truncated fragment of nonmuscle myosin II-A alters cell shape but not cytokinesis in HeLa cells. Mol Biol Cell 2000, 11:3617-3627.
159. Kahr W.H., Hinckley J., Li L., et al. Mutations in NBEAL2, encoding a BEACH protein, cause gray platelet syndrome. Nat Genet 2011, 43:738-740.
160. Albers C.A., Cvejic A., Favier R., et al. Exome sequencing identifies NBEAL2 as the causative gene for gray platelet syndrome. Nat Genet 2011, 43:735-737.
161. Gunay-Aygun M., Falik-Zaccai T.C., Vilboux T., et al. NBEAL2 is mutated in gray platelet syndrome and is required for biogenesis of platelet alpha-granules. Nat Genet 2011, 43:732-734.
162. Falik-Zaccai T.C., Anikster Y., Rivera C.E., et al. A new genetic isolate of gray platelet syndrome (GPS): clinical, cellular, and hematologic characteristics. Mol Genet Metab 2001, 74:303-313.
163. Raccuglia G. Gray platelet syndrome. A variety of qualitative platelet disorder. Am J Med 1971, 51:818-828.
164. White J.G. Ultrastructural studies of the gray platelet syndrome. Am J Pathol 1979, 95:445-462.
165. Smith M.P., Cramer E.M., Savidge G.F. Megakaryocytes and platelets in alpha-granule disorders. Baillieres Clin Haematol 1997, 10:125-148.
166. Jantunen E., Hanninen A., Naukkarinen A., Vornanen M., Lahtinen R. Gray platelet syndrome with splenomegaly and signs of extramedullary hematopoiesis: a case report with review of the literature. Am J Hematol 1994, 46:218-224.
167. Facon T., Goudemand J., Caron C., et al. Simultaneous occurrence of grey platelet syndrome and idiopathic pulmonary fibrosis: A role for abnormal megakaryocytes in the pathogenesis of pulmonary fibrosis?. Br J Haematol 1990, 74:542-543.
168. Thompson A., Wood W.G. Stamatoyannopoulos G. X-linked syndrome of platelet dysfunction, thrombocytopenia, and imbalanced globin chain synthesis with hemolysis. Blood 1977, 50:303-316.
169. Raskind W., Niakan K., Wolff J., et al. Mapping of a syndrome of X-linked thrombocytopenia with thalassemia to band Xp11-12: further evidence of genetic heterogeneity of X-linked thrombocytopenia. Blood 2000, 95:2262-2268.
170. Nichols K.E., Crispino J.D., Poncz M., et al. Familial dyserythropoietic anaemia and thrombocytopenia due to an inherited mutation in GATA1. Nat Genet 2000, 24:266-270.
171. Mehaffey M., Newton A., Gandhi M., Crossley M., Drachman J. X-linked thrombocytopenia caused by a novel mutation of GATA-1. Blood 2001, 98:2681-2688.
172. Freson K., Devriendt K., Matthijs G., et al. Platelet characteristics in patients with X-linked macrothrombocytopenia because of a novel GATA1 mutation. Blood 2001, 98:85-92.
173. Yu C., Niakan K.K., Matsushita M., Stamatoyannopoulos G., Orkin S.H., Raskind W.H. X-linked thrombocytopenia with thalassemia from a mutation in the amino finger of GATA-1 affecting DNA binding rather than FOG-1 interaction. Blood 2002, 100:2040-2045.
174. Weiss M.J., Orkin S.H. GATA transcription factors: key regulators of hematopoiesis. Exp Hematol 1995, 23:99-107.
175. Vyas P., Ault K., Jackson C., Orkin S., Shivdasani R. Consequences of GATA-1 deficiency in megakaryocytes and platelets. Blood 1999, 93:2867-2875.
176. Tsang A., Visvader J., Turner C., et al. FOG, a multitype zinc finger protein, acts as a cofactor for transcription factor GATA-1 in erythroid and megakaryocytic differentiation. Cell Mol Life Sci 1997, 90:109-119.
177. Hughan S.C., Senis Y., Best D., et al. Selective impairment of platelet activation to collagen in the absence of GATA1. Blood 2005, 105:4369-4376.
178. Ciovacco W.A., Raskind W.H., Kacena M.A. Human phenotypes associated with GATA-1 mutations. Gene 2008, 427:1-6.
179. Balduini C.L., Pecci A., Loffredo G., et al. Effects of the R216Q mutation of GATA-1 on erythropoiesis and megakaryocytopoiesis. Thromb Haemost 2004, 91:129-140.
180. Tubman V.N., Levine J.E., Campagna D.R., et al. X-linked gray platelet syndrome due to a GATA1 Arg216Gln mutation. Blood 2007, 109:3297-3299.
181. Phillips J.D., Steensma D.P., Pulsipher M.A., Spangrude G.J., Kushner J.P. Congenital erythropoietic porphyria due to a mutation in GATA1: the first trans-acting mutation causative for a human porphyria. Blood 2007, 109:2618-2621.
182. Gilman A.L., Sloand E., White J.G., Sacher R. A novel hereditary macrothrombocytopenia. J Pediatr Hematol Oncol 1995, 17:296-305.
183. Greenberg S.M., Rosenthal D.S., Greeley T.A., Tantravahi R., Handin R.I.
184. Freson K., De Vos R., Wittevrongel C., et al. The TUBB1 Q43P functional polymorphism reduces the risk of cardiovascular disease in men by modulating platelet function and structure. Blood 2005, 106:2356-2362.
185. Schwer H.D., Lecine P., Tiwari S., Italiano J.E., Hartwig J.H., Shivdasani R.A. A lineage-restricted and divergent beta-tubulin isoform is essential for the biogenesis, structure and function of blood platelets. Curr Biol 2001, 11:579-586.
186. Kunishima S., Kobayashi R., Itoh T.J., Hamaguchi M., Saito H. Mutation of the beta1-tubulin gene associated with congenital macrothrombocytopenia affecting microtubule assembly. Blood 2009, 113:458-461.
187. Rocca B., Ranelletti F.O., Maggiano N., Ciabattoni G., De Cristofaro R., Landolfi R. Inherited macrothrombocytopenia with distinctive platelet ultrastructural and functional features. Thromb Haemost 2000, 83:35-41.
188. Nurden P., Debili N., Coupry I., et al. Thrombocytopenia resulting from mutations in filamin A can be expressed as an isolated syndrome. Blood 2011, 118(22):5928-5937.